Seattle-based biotech Immusoft has moved a step closer to beginning clinical trials on one of its gene therapies, following a $3 million cash injection. The company, which is using immune system programming to develop gene therapies for illnesses such as HIV, also unveiled Sean Ainsworth as its new CEO, with Immusoft founder Matthew Scholz moving to the position of CTO.
Seattle-based biotech Immusoft has moved a step closer to beginning clinical trials on one of its gene therapies, following a $3m cash injection. The company, which is using immune system programming to develop gene therapies for illnesses such as HIV, also unveiled Sean Ainsworth as its new CEO, with Immusoft founder Matthew Scholz moving to the position of CTO.